nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP2D6—Hydroxyurea—head and neck cancer	0.144	0.446	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—head and neck cancer	0.0686	0.212	CbGbCtD
Paliperidone—CYP2D6—Vinblastine—head and neck cancer	0.0511	0.158	CbGbCtD
Paliperidone—CYP3A4—Vinblastine—head and neck cancer	0.0325	0.1	CbGbCtD
Paliperidone—CYP3A4—Docetaxel—head and neck cancer	0.0268	0.0828	CbGbCtD
Paliperidone—HTR1B—trigeminal nerve—head and neck cancer	0.0181	0.136	CbGeAlD
Paliperidone—HTR1D—trigeminal nerve—head and neck cancer	0.0175	0.131	CbGeAlD
Paliperidone—HRH1—nose—head and neck cancer	0.0133	0.0995	CbGeAlD
Paliperidone—HTR1B—cranial nerve—head and neck cancer	0.0129	0.0966	CbGeAlD
Paliperidone—HTR1D—cranial nerve—head and neck cancer	0.0125	0.0935	CbGeAlD
Paliperidone—HTR2A—trigeminal nerve—head and neck cancer	0.00869	0.0652	CbGeAlD
Paliperidone—Ileus—Vinblastine—head and neck cancer	0.0073	0.016	CcSEcCtD
Paliperidone—Sudden death—Fluorouracil—head and neck cancer	0.00663	0.0146	CcSEcCtD
Paliperidone—Balance disorder—Fluorouracil—head and neck cancer	0.00621	0.0136	CcSEcCtD
Paliperidone—HTR2A—cranial nerve—head and neck cancer	0.00619	0.0465	CbGeAlD
Paliperidone—Sinus tachycardia—Docetaxel—head and neck cancer	0.00608	0.0133	CcSEcCtD
Paliperidone—Cellulitis—Vinblastine—head and neck cancer	0.00568	0.0125	CcSEcCtD
Paliperidone—Amenorrhoea—Hydroxyurea—head and neck cancer	0.00536	0.0118	CcSEcCtD
Paliperidone—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.00498	0.0109	CcSEcCtD
Paliperidone—Photophobia—Vinblastine—head and neck cancer	0.00485	0.0107	CcSEcCtD
Paliperidone—Menstruation irregular—Docetaxel—head and neck cancer	0.00442	0.00971	CcSEcCtD
Paliperidone—Deep vein thrombosis—Docetaxel—head and neck cancer	0.00403	0.00883	CcSEcCtD
Paliperidone—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00383	0.0084	CcSEcCtD
Paliperidone—Cellulitis—Fluorouracil—head and neck cancer	0.00373	0.00819	CcSEcCtD
Paliperidone—Lacrimation increased—Fluorouracil—head and neck cancer	0.00368	0.00808	CcSEcCtD
Paliperidone—Redness—Docetaxel—head and neck cancer	0.00363	0.00796	CcSEcCtD
Paliperidone—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00363	0.00796	CcSEcCtD
Paliperidone—Intestinal obstruction—Docetaxel—head and neck cancer	0.00359	0.00788	CcSEcCtD
Paliperidone—Laryngeal pain—Docetaxel—head and neck cancer	0.00359	0.00788	CcSEcCtD
Paliperidone—Dysarthria—Fluorouracil—head and neck cancer	0.00359	0.00787	CcSEcCtD
Paliperidone—Ileus—Docetaxel—head and neck cancer	0.00346	0.00759	CcSEcCtD
Paliperidone—Face oedema—Hydroxyurea—head and neck cancer	0.0033	0.00725	CcSEcCtD
Paliperidone—Photophobia—Fluorouracil—head and neck cancer	0.00319	0.00699	CcSEcCtD
Paliperidone—Breast disorder—Hydroxyurea—head and neck cancer	0.00309	0.00679	CcSEcCtD
Paliperidone—Pancreatitis—Hydroxyurea—head and neck cancer	0.0029	0.00636	CcSEcCtD
Paliperidone—Depression—Vinblastine—head and neck cancer	0.00288	0.00633	CcSEcCtD
Paliperidone—Swelling—Fluorouracil—head and neck cancer	0.00279	0.00613	CcSEcCtD
Paliperidone—Amenorrhoea—Docetaxel—head and neck cancer	0.00279	0.00612	CcSEcCtD
Paliperidone—Chest discomfort—Docetaxel—head and neck cancer	0.00277	0.00607	CcSEcCtD
Paliperidone—Dysuria—Hydroxyurea—head and neck cancer	0.00277	0.00607	CcSEcCtD
Paliperidone—Neutropenia—Hydroxyurea—head and neck cancer	0.00277	0.00607	CcSEcCtD
Paliperidone—DRD3—head—head and neck cancer	0.0027	0.0202	CbGeAlD
Paliperidone—Agranulocytosis—Vinblastine—head and neck cancer	0.0027	0.00592	CcSEcCtD
Paliperidone—Weight increased—Hydroxyurea—head and neck cancer	0.00269	0.00591	CcSEcCtD
Paliperidone—Lacrimation increased—Docetaxel—head and neck cancer	0.00266	0.00583	CcSEcCtD
Paliperidone—Infestation—Hydroxyurea—head and neck cancer	0.00264	0.00579	CcSEcCtD
Paliperidone—Infestation NOS—Hydroxyurea—head and neck cancer	0.00264	0.00579	CcSEcCtD
Paliperidone—Hypoaesthesia—Vinblastine—head and neck cancer	0.00258	0.00567	CcSEcCtD
Paliperidone—HTR1D—connective tissue—head and neck cancer	0.00257	0.0193	CbGeAlD
Paliperidone—Lethargy—Fluorouracil—head and neck cancer	0.00251	0.00552	CcSEcCtD
Paliperidone—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00249	0.00547	CcSEcCtD
Paliperidone—Osteoarthritis—Fluorouracil—head and neck cancer	0.00246	0.00541	CcSEcCtD
Paliperidone—Pulmonary embolism—Docetaxel—head and neck cancer	0.00245	0.00537	CcSEcCtD
Paliperidone—Blood pressure increased—Docetaxel—head and neck cancer	0.00245	0.00537	CcSEcCtD
Paliperidone—Injection site reaction—Docetaxel—head and neck cancer	0.00243	0.00534	CcSEcCtD
Paliperidone—Cardiac arrest—Fluorouracil—head and neck cancer	0.00234	0.00514	CcSEcCtD
Paliperidone—Fluid retention—Docetaxel—head and neck cancer	0.00232	0.0051	CcSEcCtD
Paliperidone—Alopecia—Vinblastine—head and neck cancer	0.00229	0.00503	CcSEcCtD
Paliperidone—Dry skin—Fluorouracil—head and neck cancer	0.00226	0.00495	CcSEcCtD
Paliperidone—Nasopharyngitis—Fluorouracil—head and neck cancer	0.0022	0.00483	CcSEcCtD
Paliperidone—Muscular weakness—Fluorouracil—head and neck cancer	0.00217	0.00477	CcSEcCtD
Paliperidone—Angiopathy—Hydroxyurea—head and neck cancer	0.00215	0.00471	CcSEcCtD
Paliperidone—ADRA2C—parotid gland—head and neck cancer	0.00214	0.0161	CbGeAlD
Paliperidone—Dysphagia—Fluorouracil—head and neck cancer	0.00213	0.00467	CcSEcCtD
Paliperidone—Chills—Hydroxyurea—head and neck cancer	0.00212	0.00466	CcSEcCtD
Paliperidone—Ill-defined disorder—Vinblastine—head and neck cancer	0.0021	0.0046	CcSEcCtD
Paliperidone—Alopecia—Hydroxyurea—head and neck cancer	0.00209	0.00459	CcSEcCtD
Paliperidone—Anaemia—Vinblastine—head and neck cancer	0.00209	0.00458	CcSEcCtD
Paliperidone—ADRA1B—head—head and neck cancer	0.00207	0.0156	CbGeAlD
Paliperidone—Erythema—Hydroxyurea—head and neck cancer	0.00206	0.00452	CcSEcCtD
Paliperidone—Malaise—Vinblastine—head and neck cancer	0.00204	0.00447	CcSEcCtD
Paliperidone—Vertigo—Vinblastine—head and neck cancer	0.00203	0.00446	CcSEcCtD
Paliperidone—Leukopenia—Vinblastine—head and neck cancer	0.00202	0.00444	CcSEcCtD
Paliperidone—Swelling—Docetaxel—head and neck cancer	0.00201	0.00442	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00198	0.00434	CcSEcCtD
Paliperidone—Convulsion—Vinblastine—head and neck cancer	0.00196	0.0043	CcSEcCtD
Paliperidone—Hypertension—Vinblastine—head and neck cancer	0.00195	0.00428	CcSEcCtD
Paliperidone—DRD1—head—head and neck cancer	0.00193	0.0145	CbGeAlD
Paliperidone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00191	0.0042	CcSEcCtD
Paliperidone—Pneumonia—Fluorouracil—head and neck cancer	0.00191	0.00419	CcSEcCtD
Paliperidone—Anaemia—Hydroxyurea—head and neck cancer	0.0019	0.00418	CcSEcCtD
Paliperidone—Discomfort—Vinblastine—head and neck cancer	0.0019	0.00417	CcSEcCtD
Paliperidone—Infestation NOS—Fluorouracil—head and neck cancer	0.0019	0.00417	CcSEcCtD
Paliperidone—Infestation—Fluorouracil—head and neck cancer	0.0019	0.00417	CcSEcCtD
Paliperidone—ADRA1A—epithelium—head and neck cancer	0.00188	0.0141	CbGeAlD
Paliperidone—Atrial fibrillation—Docetaxel—head and neck cancer	0.00188	0.00412	CcSEcCtD
Paliperidone—Malaise—Hydroxyurea—head and neck cancer	0.00186	0.00408	CcSEcCtD
Paliperidone—Urinary tract infection—Fluorouracil—head and neck cancer	0.00184	0.00405	CcSEcCtD
Paliperidone—Conjunctivitis—Fluorouracil—head and neck cancer	0.00184	0.00405	CcSEcCtD
Paliperidone—Leukopenia—Hydroxyurea—head and neck cancer	0.00184	0.00405	CcSEcCtD
Paliperidone—Lethargy—Docetaxel—head and neck cancer	0.00181	0.00398	CcSEcCtD
Paliperidone—Thrombocytopenia—Vinblastine—head and neck cancer	0.00181	0.00396	CcSEcCtD
Paliperidone—Epistaxis—Fluorouracil—head and neck cancer	0.00179	0.00393	CcSEcCtD
Paliperidone—Convulsion—Hydroxyurea—head and neck cancer	0.00179	0.00392	CcSEcCtD
Paliperidone—HTR2A—neck—head and neck cancer	0.00178	0.0134	CbGeAlD
Paliperidone—Sinusitis—Fluorouracil—head and neck cancer	0.00178	0.00391	CcSEcCtD
Paliperidone—Pain in extremity—Docetaxel—head and neck cancer	0.00178	0.0039	CcSEcCtD
Paliperidone—Agranulocytosis—Fluorouracil—head and neck cancer	0.00177	0.00389	CcSEcCtD
Paliperidone—Anorexia—Vinblastine—head and neck cancer	0.00176	0.00386	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00174	0.00382	CcSEcCtD
Paliperidone—Discomfort—Hydroxyurea—head and neck cancer	0.00173	0.0038	CcSEcCtD
Paliperidone—Rhinitis—Fluorouracil—head and neck cancer	0.00171	0.00375	CcSEcCtD
Paliperidone—Hypoaesthesia—Fluorouracil—head and neck cancer	0.0017	0.00372	CcSEcCtD
Paliperidone—Oedema—Hydroxyurea—head and neck cancer	0.00168	0.00369	CcSEcCtD
Paliperidone—Infection—Hydroxyurea—head and neck cancer	0.00167	0.00367	CcSEcCtD
Paliperidone—Paraesthesia—Vinblastine—head and neck cancer	0.00166	0.00363	CcSEcCtD
Paliperidone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00165	0.00362	CcSEcCtD
Paliperidone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00165	0.00361	CcSEcCtD
Paliperidone—Skin disorder—Hydroxyurea—head and neck cancer	0.00163	0.00359	CcSEcCtD
Paliperidone—Dry skin—Docetaxel—head and neck cancer	0.00163	0.00358	CcSEcCtD
Paliperidone—Abdominal pain upper—Docetaxel—head and neck cancer	0.00162	0.00356	CcSEcCtD
Paliperidone—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00162	0.00356	CcSEcCtD
Paliperidone—Breast disorder—Docetaxel—head and neck cancer	0.00161	0.00353	CcSEcCtD
Paliperidone—Anorexia—Hydroxyurea—head and neck cancer	0.0016	0.00352	CcSEcCtD
Paliperidone—Decreased appetite—Vinblastine—head and neck cancer	0.0016	0.00352	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.0016	0.00351	CcSEcCtD
Paliperidone—Nasopharyngitis—Docetaxel—head and neck cancer	0.00159	0.00349	CcSEcCtD
Paliperidone—ADRA2C—trachea—head and neck cancer	0.00158	0.0119	CbGeAlD
Paliperidone—Constipation—Vinblastine—head and neck cancer	0.00158	0.00346	CcSEcCtD
Paliperidone—Pain—Vinblastine—head and neck cancer	0.00158	0.00346	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00157	0.00344	CcSEcCtD
Paliperidone—HTR1B—head—head and neck cancer	0.00157	0.0117	CbGeAlD
Paliperidone—Dysphagia—Docetaxel—head and neck cancer	0.00154	0.00337	CcSEcCtD
Paliperidone—HRH1—connective tissue—head and neck cancer	0.00153	0.0115	CbGeAlD
Paliperidone—Feeling abnormal—Vinblastine—head and neck cancer	0.00152	0.00334	CcSEcCtD
Paliperidone—HTR1D—head—head and neck cancer	0.00152	0.0114	CbGeAlD
Paliperidone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00151	0.00331	CcSEcCtD
Paliperidone—Alopecia—Fluorouracil—head and neck cancer	0.00151	0.0033	CcSEcCtD
Paliperidone—ADRA2A—connective tissue—head and neck cancer	0.0015	0.0113	CbGeAlD
Paliperidone—HTR2C—head—head and neck cancer	0.0015	0.0113	CbGeAlD
Paliperidone—Dyspnoea—Hydroxyurea—head and neck cancer	0.0015	0.00329	CcSEcCtD
Paliperidone—Somnolence—Hydroxyurea—head and neck cancer	0.0015	0.00328	CcSEcCtD
Paliperidone—Erythema—Fluorouracil—head and neck cancer	0.00148	0.00326	CcSEcCtD
Paliperidone—Dyspepsia—Hydroxyurea—head and neck cancer	0.00148	0.00325	CcSEcCtD
Paliperidone—Decreased appetite—Hydroxyurea—head and neck cancer	0.00146	0.00321	CcSEcCtD
Paliperidone—Abdominal pain—Vinblastine—head and neck cancer	0.00146	0.0032	CcSEcCtD
Paliperidone—HRH1—epithelium—head and neck cancer	0.00145	0.0109	CbGeAlD
Paliperidone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00145	0.00319	CcSEcCtD
Paliperidone—Fatigue—Hydroxyurea—head and neck cancer	0.00145	0.00318	CcSEcCtD
Paliperidone—ADRA1A—lymphoid tissue—head and neck cancer	0.00145	0.0108	CbGeAlD
Paliperidone—Pain—Hydroxyurea—head and neck cancer	0.00144	0.00316	CcSEcCtD
Paliperidone—Constipation—Hydroxyurea—head and neck cancer	0.00144	0.00316	CcSEcCtD
Paliperidone—Neutropenia—Docetaxel—head and neck cancer	0.00144	0.00315	CcSEcCtD
Paliperidone—Weight increased—Docetaxel—head and neck cancer	0.0014	0.00307	CcSEcCtD
Paliperidone—Vision blurred—Fluorouracil—head and neck cancer	0.0014	0.00307	CcSEcCtD
Paliperidone—Weight decreased—Docetaxel—head and neck cancer	0.00139	0.00305	CcSEcCtD
Paliperidone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00139	0.00304	CcSEcCtD
Paliperidone—Pneumonia—Docetaxel—head and neck cancer	0.00138	0.00302	CcSEcCtD
Paliperidone—Anaemia—Fluorouracil—head and neck cancer	0.00137	0.00301	CcSEcCtD
Paliperidone—Infestation—Docetaxel—head and neck cancer	0.00137	0.00301	CcSEcCtD
Paliperidone—Infestation NOS—Docetaxel—head and neck cancer	0.00137	0.00301	CcSEcCtD
Paliperidone—Hypersensitivity—Vinblastine—head and neck cancer	0.00136	0.00298	CcSEcCtD
Paliperidone—Jaundice—Docetaxel—head and neck cancer	0.00134	0.00293	CcSEcCtD
Paliperidone—Conjunctivitis—Docetaxel—head and neck cancer	0.00133	0.00292	CcSEcCtD
Paliperidone—Body temperature increased—Hydroxyurea—head and neck cancer	0.00133	0.00292	CcSEcCtD
Paliperidone—Leukopenia—Fluorouracil—head and neck cancer	0.00133	0.00291	CcSEcCtD
Paliperidone—Asthenia—Vinblastine—head and neck cancer	0.00132	0.0029	CcSEcCtD
Paliperidone—Hepatobiliary disease—Docetaxel—head and neck cancer	0.0013	0.00284	CcSEcCtD
Paliperidone—Epistaxis—Docetaxel—head and neck cancer	0.00129	0.00284	CcSEcCtD
Paliperidone—Convulsion—Fluorouracil—head and neck cancer	0.00129	0.00282	CcSEcCtD
Paliperidone—HRH1—trachea—head and neck cancer	0.00128	0.00964	CbGeAlD
Paliperidone—Agranulocytosis—Docetaxel—head and neck cancer	0.00128	0.00281	CcSEcCtD
Paliperidone—HTR2A—connective tissue—head and neck cancer	0.00128	0.00959	CbGeAlD
Paliperidone—HTR1A—head—head and neck cancer	0.00126	0.00948	CbGeAlD
Paliperidone—Myalgia—Fluorouracil—head and neck cancer	0.00126	0.00277	CcSEcCtD
Paliperidone—Chest pain—Fluorouracil—head and neck cancer	0.00126	0.00277	CcSEcCtD
Paliperidone—ADRA2A—trachea—head and neck cancer	0.00126	0.00947	CbGeAlD
Paliperidone—Diarrhoea—Vinblastine—head and neck cancer	0.00126	0.00277	CcSEcCtD
Paliperidone—Discomfort—Fluorouracil—head and neck cancer	0.00125	0.00274	CcSEcCtD
Paliperidone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00124	0.00272	CcSEcCtD
Paliperidone—Rhinitis—Docetaxel—head and neck cancer	0.00123	0.00271	CcSEcCtD
Paliperidone—Hypoaesthesia—Docetaxel—head and neck cancer	0.00122	0.00269	CcSEcCtD
Paliperidone—Confusional state—Fluorouracil—head and neck cancer	0.00122	0.00268	CcSEcCtD
Paliperidone—Dizziness—Vinblastine—head and neck cancer	0.00122	0.00268	CcSEcCtD
Paliperidone—Urinary tract disorder—Docetaxel—head and neck cancer	0.00121	0.00267	CcSEcCtD
Paliperidone—HTR2A—epithelium—head and neck cancer	0.00121	0.0091	CbGeAlD
Paliperidone—Oedema peripheral—Docetaxel—head and neck cancer	0.00121	0.00266	CcSEcCtD
Paliperidone—Oedema—Fluorouracil—head and neck cancer	0.00121	0.00266	CcSEcCtD
Paliperidone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00121	0.00266	CcSEcCtD
Paliperidone—Connective tissue disorder—Docetaxel—head and neck cancer	0.00121	0.00265	CcSEcCtD
Paliperidone—Asthenia—Hydroxyurea—head and neck cancer	0.00121	0.00265	CcSEcCtD
Paliperidone—Urethral disorder—Docetaxel—head and neck cancer	0.00121	0.00265	CcSEcCtD
Paliperidone—Infection—Fluorouracil—head and neck cancer	0.0012	0.00264	CcSEcCtD
Paliperidone—Nervous system disorder—Fluorouracil—head and neck cancer	0.00119	0.00261	CcSEcCtD
Paliperidone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00119	0.0026	CcSEcCtD
Paliperidone—Tachycardia—Fluorouracil—head and neck cancer	0.00118	0.00259	CcSEcCtD
Paliperidone—Vomiting—Vinblastine—head and neck cancer	0.00117	0.00257	CcSEcCtD
Paliperidone—ADRA1A—head—head and neck cancer	0.00116	0.00874	CbGeAlD
Paliperidone—Headache—Vinblastine—head and neck cancer	0.00116	0.00254	CcSEcCtD
Paliperidone—Anorexia—Fluorouracil—head and neck cancer	0.00115	0.00253	CcSEcCtD
Paliperidone—Diarrhoea—Hydroxyurea—head and neck cancer	0.00115	0.00253	CcSEcCtD
Paliperidone—Eye disorder—Docetaxel—head and neck cancer	0.00115	0.00252	CcSEcCtD
Paliperidone—DRD2—head—head and neck cancer	0.00114	0.00856	CbGeAlD
Paliperidone—Cardiac disorder—Docetaxel—head and neck cancer	0.00114	0.0025	CcSEcCtD
Paliperidone—Flushing—Docetaxel—head and neck cancer	0.00114	0.0025	CcSEcCtD
Paliperidone—Hypotension—Fluorouracil—head and neck cancer	0.00113	0.00248	CcSEcCtD
Paliperidone—Angiopathy—Docetaxel—head and neck cancer	0.00112	0.00245	CcSEcCtD
Paliperidone—Dizziness—Hydroxyurea—head and neck cancer	0.00111	0.00244	CcSEcCtD
Paliperidone—Immune system disorder—Docetaxel—head and neck cancer	0.00111	0.00244	CcSEcCtD
Paliperidone—ADRA2C—head—head and neck cancer	0.00111	0.00833	CbGeAlD
Paliperidone—Mediastinal disorder—Docetaxel—head and neck cancer	0.00111	0.00243	CcSEcCtD
Paliperidone—Chills—Docetaxel—head and neck cancer	0.0011	0.00242	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.0011	0.00242	CcSEcCtD
Paliperidone—Nausea—Vinblastine—head and neck cancer	0.0011	0.0024	CcSEcCtD
Paliperidone—Insomnia—Fluorouracil—head and neck cancer	0.00109	0.0024	CcSEcCtD
Paliperidone—Paraesthesia—Fluorouracil—head and neck cancer	0.00109	0.00239	CcSEcCtD
Paliperidone—Alopecia—Docetaxel—head and neck cancer	0.00109	0.00238	CcSEcCtD
Paliperidone—Dyspnoea—Fluorouracil—head and neck cancer	0.00108	0.00237	CcSEcCtD
Paliperidone—Mental disorder—Docetaxel—head and neck cancer	0.00108	0.00236	CcSEcCtD
Paliperidone—Somnolence—Fluorouracil—head and neck cancer	0.00108	0.00236	CcSEcCtD
Paliperidone—HTR2A—trachea—head and neck cancer	0.00107	0.00805	CbGeAlD
Paliperidone—Malnutrition—Docetaxel—head and neck cancer	0.00107	0.00235	CcSEcCtD
Paliperidone—Erythema—Docetaxel—head and neck cancer	0.00107	0.00235	CcSEcCtD
Paliperidone—Vomiting—Hydroxyurea—head and neck cancer	0.00107	0.00235	CcSEcCtD
Paliperidone—Dyspepsia—Fluorouracil—head and neck cancer	0.00107	0.00234	CcSEcCtD
Paliperidone—Rash—Hydroxyurea—head and neck cancer	0.00106	0.00233	CcSEcCtD
Paliperidone—Dermatitis—Hydroxyurea—head and neck cancer	0.00106	0.00233	CcSEcCtD
Paliperidone—Headache—Hydroxyurea—head and neck cancer	0.00105	0.00231	CcSEcCtD
Paliperidone—Decreased appetite—Fluorouracil—head and neck cancer	0.00105	0.00231	CcSEcCtD
Paliperidone—Dysgeusia—Docetaxel—head and neck cancer	0.00105	0.0023	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00105	0.00229	CcSEcCtD
Paliperidone—Back pain—Docetaxel—head and neck cancer	0.00104	0.00227	CcSEcCtD
Paliperidone—Pain—Fluorouracil—head and neck cancer	0.00104	0.00227	CcSEcCtD
Paliperidone—Muscle spasms—Docetaxel—head and neck cancer	0.00103	0.00226	CcSEcCtD
Paliperidone—Nausea—Hydroxyurea—head and neck cancer	0.000999	0.00219	CcSEcCtD
Paliperidone—ADRA2A—thyroid gland—head and neck cancer	0.000998	0.00749	CbGeAlD
Paliperidone—Feeling abnormal—Fluorouracil—head and neck cancer	0.000997	0.00219	CcSEcCtD
Paliperidone—Anaemia—Docetaxel—head and neck cancer	0.000989	0.00217	CcSEcCtD
Paliperidone—Urticaria—Fluorouracil—head and neck cancer	0.000962	0.00211	CcSEcCtD
Paliperidone—Syncope—Docetaxel—head and neck cancer	0.00096	0.00211	CcSEcCtD
Paliperidone—Leukopenia—Docetaxel—head and neck cancer	0.000958	0.0021	CcSEcCtD
Paliperidone—Body temperature increased—Fluorouracil—head and neck cancer	0.000957	0.0021	CcSEcCtD
Paliperidone—Palpitations—Docetaxel—head and neck cancer	0.000946	0.00208	CcSEcCtD
Paliperidone—Loss of consciousness—Docetaxel—head and neck cancer	0.000941	0.00207	CcSEcCtD
Paliperidone—Cough—Docetaxel—head and neck cancer	0.000934	0.00205	CcSEcCtD
Paliperidone—Convulsion—Docetaxel—head and neck cancer	0.000928	0.00204	CcSEcCtD
Paliperidone—Hypertension—Docetaxel—head and neck cancer	0.000924	0.00203	CcSEcCtD
Paliperidone—Myalgia—Docetaxel—head and neck cancer	0.000911	0.002	CcSEcCtD
Paliperidone—Chest pain—Docetaxel—head and neck cancer	0.000911	0.002	CcSEcCtD
Paliperidone—Arthralgia—Docetaxel—head and neck cancer	0.000911	0.002	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000905	0.00199	CcSEcCtD
Paliperidone—HRH1—head—head and neck cancer	0.000902	0.00676	CbGeAlD
Paliperidone—Hypersensitivity—Fluorouracil—head and neck cancer	0.000892	0.00196	CcSEcCtD
Paliperidone—Dry mouth—Docetaxel—head and neck cancer	0.000891	0.00196	CcSEcCtD
Paliperidone—ADRA2A—head—head and neck cancer	0.000886	0.00664	CbGeAlD
Paliperidone—Confusional state—Docetaxel—head and neck cancer	0.000881	0.00193	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—head and neck cancer	0.000874	0.00192	CcSEcCtD
Paliperidone—Oedema—Docetaxel—head and neck cancer	0.000874	0.00192	CcSEcCtD
Paliperidone—Infection—Docetaxel—head and neck cancer	0.000868	0.0019	CcSEcCtD
Paliperidone—Shock—Docetaxel—head and neck cancer	0.00086	0.00189	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—head and neck cancer	0.000857	0.00188	CcSEcCtD
Paliperidone—Pruritus—Fluorouracil—head and neck cancer	0.000856	0.00188	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—head and neck cancer	0.000855	0.00188	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—head and neck cancer	0.000853	0.00187	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—head and neck cancer	0.000849	0.00186	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—head and neck cancer	0.000833	0.00183	CcSEcCtD
Paliperidone—Diarrhoea—Fluorouracil—head and neck cancer	0.000828	0.00182	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—head and neck cancer	0.000816	0.00179	CcSEcCtD
Paliperidone—Dizziness—Fluorouracil—head and neck cancer	0.0008	0.00176	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000796	0.00175	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—head and neck cancer	0.00079	0.00173	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—head and neck cancer	0.000785	0.00172	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—head and neck cancer	0.000779	0.00171	CcSEcCtD
Paliperidone—ADRA2C—lymph node—head and neck cancer	0.000777	0.00583	CbGeAlD
Paliperidone—Somnolence—Docetaxel—head and neck cancer	0.000777	0.0017	CcSEcCtD
Paliperidone—Vomiting—Fluorouracil—head and neck cancer	0.00077	0.00169	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—head and neck cancer	0.000769	0.00169	CcSEcCtD
Paliperidone—Rash—Fluorouracil—head and neck cancer	0.000763	0.00168	CcSEcCtD
Paliperidone—Dermatitis—Fluorouracil—head and neck cancer	0.000763	0.00167	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—head and neck cancer	0.000759	0.00167	CcSEcCtD
Paliperidone—Headache—Fluorouracil—head and neck cancer	0.000758	0.00166	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000754	0.00166	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—head and neck cancer	0.000753	0.00165	CcSEcCtD
Paliperidone—HTR2A—head—head and neck cancer	0.000753	0.00565	CbGeAlD
Paliperidone—Constipation—Docetaxel—head and neck cancer	0.000747	0.00164	CcSEcCtD
Paliperidone—Pain—Docetaxel—head and neck cancer	0.000747	0.00164	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—head and neck cancer	0.00072	0.00158	CcSEcCtD
Paliperidone—Nausea—Fluorouracil—head and neck cancer	0.000719	0.00158	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000714	0.00157	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—head and neck cancer	0.000691	0.00152	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—head and neck cancer	0.000691	0.00152	CcSEcCtD
Paliperidone—CYP2D6—head—head and neck cancer	0.000686	0.00515	CbGeAlD
Paliperidone—Hypersensitivity—Docetaxel—head and neck cancer	0.000644	0.00141	CcSEcCtD
Paliperidone—HRH1—lymph node—head and neck cancer	0.000631	0.00474	CbGeAlD
Paliperidone—Asthenia—Docetaxel—head and neck cancer	0.000627	0.00138	CcSEcCtD
Paliperidone—ADRA2A—lymph node—head and neck cancer	0.00062	0.00465	CbGeAlD
Paliperidone—Pruritus—Docetaxel—head and neck cancer	0.000618	0.00136	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—head and neck cancer	0.000598	0.00131	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—head and neck cancer	0.000578	0.00127	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—head and neck cancer	0.000555	0.00122	CcSEcCtD
Paliperidone—Rash—Docetaxel—head and neck cancer	0.000551	0.00121	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—head and neck cancer	0.00055	0.00121	CcSEcCtD
Paliperidone—Headache—Docetaxel—head and neck cancer	0.000547	0.0012	CcSEcCtD
Paliperidone—Nausea—Docetaxel—head and neck cancer	0.000519	0.00114	CcSEcCtD
Paliperidone—DRD2—Signaling by GPCR—MAPK1—head and neck cancer	2.17e-05	0.000247	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—EGFR—head and neck cancer	2.17e-05	0.000246	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CCND1—head and neck cancer	2.16e-05	0.000246	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—STAT3—head and neck cancer	2.15e-05	0.000245	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—PIK3CA—head and neck cancer	2.14e-05	0.000244	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GPX1—head and neck cancer	2.14e-05	0.000243	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	2.13e-05	0.000243	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CCND1—head and neck cancer	2.13e-05	0.000243	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	2.13e-05	0.000243	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	2.13e-05	0.000242	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—MAPK1—head and neck cancer	2.13e-05	0.000242	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EGFR—head and neck cancer	2.13e-05	0.000242	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—head and neck cancer	2.13e-05	0.000242	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP1A1—head and neck cancer	2.12e-05	0.000241	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—STAT3—head and neck cancer	2.1e-05	0.00024	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—head and neck cancer	2.09e-05	0.000238	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—MAPK1—head and neck cancer	2.09e-05	0.000238	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EGFR—head and neck cancer	2.09e-05	0.000237	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PTEN—head and neck cancer	2.08e-05	0.000237	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PTEN—head and neck cancer	2.07e-05	0.000236	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—PIK3CA—head and neck cancer	2.07e-05	0.000236	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—STAT3—head and neck cancer	2.07e-05	0.000236	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	2.07e-05	0.000236	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PTEN—head and neck cancer	2.06e-05	0.000234	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MAPK3—head and neck cancer	2.05e-05	0.000234	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	2.05e-05	0.000234	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	2.04e-05	0.000232	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	2.04e-05	0.000232	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	2.04e-05	0.000232	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—AKT1—head and neck cancer	2.03e-05	0.000231	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.03e-05	0.000231	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	2.01e-05	0.000229	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—AKT1—head and neck cancer	2.01e-05	0.000228	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	2e-05	0.000227	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.99e-05	0.000227	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	1.98e-05	0.000225	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MAPK3—head and neck cancer	1.98e-05	0.000225	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL2—head and neck cancer	1.97e-05	0.000225	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.97e-05	0.000224	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MAPK1—head and neck cancer	1.95e-05	0.000222	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EGFR—head and neck cancer	1.95e-05	0.000222	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	1.94e-05	0.000221	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	1.94e-05	0.000221	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—head and neck cancer	1.93e-05	0.00022	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	1.93e-05	0.000219	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	1.92e-05	0.000219	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—HRAS—head and neck cancer	1.92e-05	0.000218	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.92e-05	0.000218	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	1.91e-05	0.000218	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EGFR—head and neck cancer	1.91e-05	0.000218	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL2—head and neck cancer	1.91e-05	0.000217	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.9e-05	0.000216	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	1.89e-05	0.000215	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—head and neck cancer	1.88e-05	0.000214	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MAPK1—head and neck cancer	1.88e-05	0.000214	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EGFR—head and neck cancer	1.88e-05	0.000214	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	1.88e-05	0.000214	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—STAT3—head and neck cancer	1.86e-05	0.000212	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—AKT1—head and neck cancer	1.86e-05	0.000212	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—head and neck cancer	1.86e-05	0.000211	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CCND1—head and neck cancer	1.86e-05	0.000211	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	1.86e-05	0.000211	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.85e-05	0.000211	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.85e-05	0.00021	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.85e-05	0.00021	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	1.85e-05	0.00021	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL2—head and neck cancer	1.84e-05	0.00021	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—STAT3—head and neck cancer	1.84e-05	0.000209	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	1.83e-05	0.000209	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL2—head and neck cancer	1.81e-05	0.000206	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	1.81e-05	0.000206	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	1.81e-05	0.000206	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	1.8e-05	0.000205	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.79e-05	0.000204	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.78e-05	0.000203	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK3—head and neck cancer	1.78e-05	0.000203	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.77e-05	0.000202	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	1.77e-05	0.000201	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK3—head and neck cancer	1.76e-05	0.0002	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.75e-05	0.000199	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.74e-05	0.000198	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HRAS—head and neck cancer	1.74e-05	0.000198	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	1.73e-05	0.000197	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.71e-05	0.000195	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.71e-05	0.000194	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	1.71e-05	0.000194	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	1.7e-05	0.000193	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK1—head and neck cancer	1.7e-05	0.000193	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—head and neck cancer	1.69e-05	0.000193	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	1.69e-05	0.000193	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	1.69e-05	0.000192	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTEN—head and neck cancer	1.69e-05	0.000192	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.68e-05	0.000191	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	1.68e-05	0.000191	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.68e-05	0.000191	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—head and neck cancer	1.67e-05	0.00019	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK1—head and neck cancer	1.67e-05	0.00019	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—head and neck cancer	1.67e-05	0.00019	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	1.67e-05	0.00019	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.66e-05	0.000189	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	1.66e-05	0.000189	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.66e-05	0.000189	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	1.66e-05	0.000189	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.65e-05	0.000187	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—head and neck cancer	1.64e-05	0.000187	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—head and neck cancer	1.64e-05	0.000187	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—head and neck cancer	1.63e-05	0.000186	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—head and neck cancer	1.63e-05	0.000186	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.63e-05	0.000185	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.62e-05	0.000184	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.61e-05	0.000183	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.61e-05	0.000183	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—head and neck cancer	1.61e-05	0.000183	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.6e-05	0.000183	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.6e-05	0.000182	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.6e-05	0.000182	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.6e-05	0.000182	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	1.59e-05	0.000181	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—head and neck cancer	1.58e-05	0.00018	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—head and neck cancer	1.57e-05	0.000179	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.57e-05	0.000179	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—head and neck cancer	1.57e-05	0.000179	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	1.57e-05	0.000178	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	1.56e-05	0.000177	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	1.55e-05	0.000177	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.55e-05	0.000176	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—head and neck cancer	1.55e-05	0.000176	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—head and neck cancer	1.54e-05	0.000176	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	1.54e-05	0.000175	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—head and neck cancer	1.54e-05	0.000175	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—head and neck cancer	1.54e-05	0.000175	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	1.53e-05	0.000174	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	1.53e-05	0.000174	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.52e-05	0.000173	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	1.52e-05	0.000173	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—head and neck cancer	1.51e-05	0.000172	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—head and neck cancer	1.5e-05	0.00017	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	1.48e-05	0.000169	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	1.48e-05	0.000168	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TYMS—head and neck cancer	1.48e-05	0.000168	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—head and neck cancer	1.47e-05	0.000167	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—head and neck cancer	1.46e-05	0.000167	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.46e-05	0.000166	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	1.46e-05	0.000166	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	1.46e-05	0.000166	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	1.46e-05	0.000166	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—head and neck cancer	1.46e-05	0.000166	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	1.45e-05	0.000165	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.45e-05	0.000165	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.45e-05	0.000165	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—head and neck cancer	1.42e-05	0.000162	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—head and neck cancer	1.42e-05	0.000162	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	1.41e-05	0.00016	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	1.41e-05	0.00016	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	1.41e-05	0.00016	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—head and neck cancer	1.41e-05	0.00016	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—head and neck cancer	1.4e-05	0.00016	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1.4e-05	0.000159	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GPX1—head and neck cancer	1.4e-05	0.000159	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—head and neck cancer	1.4e-05	0.000159	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	1.39e-05	0.000158	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	1.39e-05	0.000158	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—head and neck cancer	1.39e-05	0.000158	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—head and neck cancer	1.39e-05	0.000158	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.38e-05	0.000158	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—head and neck cancer	1.38e-05	0.000157	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	1.37e-05	0.000156	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	1.37e-05	0.000156	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—head and neck cancer	1.36e-05	0.000155	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—head and neck cancer	1.36e-05	0.000154	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	1.36e-05	0.000154	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—head and neck cancer	1.35e-05	0.000153	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—head and neck cancer	1.34e-05	0.000153	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—head and neck cancer	1.33e-05	0.000152	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	1.32e-05	0.000151	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—head and neck cancer	1.32e-05	0.00015	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	1.31e-05	0.000149	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	1.3e-05	0.000147	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK1—head and neck cancer	1.28e-05	0.000146	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—head and neck cancer	1.28e-05	0.000146	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	1.27e-05	0.000145	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—head and neck cancer	1.27e-05	0.000144	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	1.26e-05	0.000144	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK1—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—head and neck cancer	1.26e-05	0.000143	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	1.23e-05	0.00014	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	1.23e-05	0.00014	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	1.22e-05	0.000139	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—head and neck cancer	1.22e-05	0.000139	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.22e-05	0.000139	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	1.21e-05	0.000138	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	1.2e-05	0.000137	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	1.2e-05	0.000137	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—head and neck cancer	1.2e-05	0.000137	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—head and neck cancer	1.2e-05	0.000136	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—head and neck cancer	1.19e-05	0.000135	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—head and neck cancer	1.19e-05	0.000135	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—head and neck cancer	1.18e-05	0.000135	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—head and neck cancer	1.17e-05	0.000133	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—head and neck cancer	1.17e-05	0.000133	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.16e-05	0.000132	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	1.15e-05	0.00013	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	1.15e-05	0.00013	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	1.13e-05	0.000129	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	1.11e-05	0.000127	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	1.11e-05	0.000126	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—head and neck cancer	1.1e-05	0.000125	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	1.09e-05	0.000124	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	1.09e-05	0.000124	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.09e-05	0.000124	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—head and neck cancer	1.07e-05	0.000122	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	1.07e-05	0.000122	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	1.07e-05	0.000122	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—head and neck cancer	1.06e-05	0.00012	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—head and neck cancer	1.05e-05	0.00012	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—head and neck cancer	1.04e-05	0.000118	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—head and neck cancer	1.03e-05	0.000118	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—head and neck cancer	1.03e-05	0.000117	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—head and neck cancer	1.03e-05	0.000117	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—head and neck cancer	1.01e-05	0.000115	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—head and neck cancer	1.01e-05	0.000115	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	1e-05	0.000114	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	9.94e-06	0.000113	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	9.9e-06	0.000113	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	9.84e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—head and neck cancer	9.71e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—head and neck cancer	9.62e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	9.2e-06	0.000105	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—head and neck cancer	9.07e-06	0.000103	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—head and neck cancer	8.93e-06	0.000102	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—head and neck cancer	8.91e-06	0.000101	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—head and neck cancer	8.9e-06	0.000101	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	8.74e-06	9.95e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—head and neck cancer	8.23e-06	9.37e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	8.12e-06	9.24e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—head and neck cancer	7.75e-06	8.82e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—head and neck cancer	7.18e-06	8.17e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—head and neck cancer	6.33e-06	7.2e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—head and neck cancer	5.07e-06	5.76e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—head and neck cancer	4.14e-06	4.71e-05	CbGpPWpGaD
